The two most common forms of HGGs are glioblastoma (GBM) and
anaplastic astrocytoma.
2006) documented significantly lower levels of serum IL-12 and higher levels of IL-10 among newly diagnosed patients with
anaplastic astrocytoma and GBM.
Interestingly, of the 15 patients with
anaplastic astrocytoma, all who had normal serum AHSG (n = 5) survived >2 years, whereas those with low serum AHSG (n = 10) had a median survival of <10 months.
A snapshot of the global therapeutic scenario for
Anaplastic Astrocytoma.
This product is the generic equivalent to TemodarA (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory
anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
2) Anaplastic gliomas are characterized by loss of 9p and homozygous deletion of the CDKN2A/B gene (p16/p15), and the progression of an
anaplastic astrocytoma to a secondary GBM is frequently associated with 10q loss.
Further analysis of their data showed that glioblastoma and
anaplastic astrocytoma patients carrying the mutations survived longer than those who did not, and note that additional studies of how the gene works may reveal why this occurs.
TEMODAL is currently marketed in Canada for the treatment of recurrent or progressive GBM or
anaplastic astrocytoma (AA), another form of brain tumor.
She then presented with increased seizure activity, and a biopsy confirmed a more aggressive tumor--an
anaplastic astrocytoma.
GlobalData's clinical trial report,
Anaplastic Astrocytoma Global Clinical Trials Review, H1, 2012" provides data on the
Anaplastic Astrocytoma clinical trial scenario.
The company's lead investigational combination product, Toca 511 & Toca FC, is advancing into a pivotal Phase 2/3 study in 2015 for patients with recurrent glioblastoma or
anaplastic astrocytoma.
For example, it uses mitotic activity to distinguish
anaplastic astrocytoma (AA), WHO grade III, from its low-grade counterpart, diffuse astrocytoma, WHO grade II.
